Description
Buprenorphine Sublingual Tablets (0.4 mg / 2 mg / 8 mg)
Healthy Inc is a specialized global supplier and exporter of advanced CNS, pain management, and addiction medicine therapeutics. We provide ultra-high-purity, kinetically optimized Buprenorphine Sublingual Tablets, manufactured in WHO–GMP certified, high-security specialized narcotic containment facilities. This “Partial Mu-Opioid Agonist” is a premium strategic export to detoxification centers, palliative care units, and government health ministries, serving as the globally mandated intervention for Opioid Use Disorder (OUD) and severe chronic pain.
Product Overview
This formulation operates as a high-affinity “Receptor Occupier.” Buprenorphine binds so tightly to the brain’s opioid receptors that it displaces other opioids while only partially activating the receptor, preventing withdrawal without causing a “high.”
Mechanism 1 (Partial Mu-Agonism): Buprenorphine binds to the Mu-Opioid Receptors but only partially activates them. This provides enough stimulation to stop cravings and withdrawal symptoms but reaches a “Ceiling Effect” where higher doses do not produce more euphoria or dangerous respiratory depression.
Mechanism 2 (Kappa-Antagonism): It acts as an antagonist at Kappa-Opioid Receptors, which is believed to contribute to its antidepressant-like effects and its ability to reduce the “dysphoria” associated with drug withdrawal.
Mechanism 3 (The High-Affinity Shield): Because it has a higher affinity for receptors than Heroin or Methadone, it physically blocks other opioids from binding. If a patient uses another opioid while on Buprenorphine, they will feel no effect.
Technical & Logistics Specifications
HS Code: 3004.90.61 (Medicaments containing alkaloids – Buprenorphine)
CAS Number: 52485-79-7 (Buprenorphine) / 53152-21-9 (Buprenorphine HCl)
Dosage Form: Sublingual Tablet (Uncoated)
Packaging: Alu-Alu Blisters (MANDATORY). Protects the sensitive API from moisture and provides a tamper-evident barrier.
Manufacturing Authority & Compliance
Narcotic Security (Schedule II/III): Our facility operates under Strict Government License with end-to-end vault storage, 24/7 surveillance, and rigorous “Chain of Custody” protocols for all Buprenorphine shipments.
Sublingual Bioavailability Mastery: Since Buprenorphine has a high “First-Pass Metabolism” (it is destroyed by the liver if swallowed), our tablets are engineered for Transmucosal Absorption. We guarantee a specific pH-optimized matrix that ensures the drug enters the bloodstream directly via the sublingual vein.
Primary Indications
Addiction Medicine: Substitution treatment for opioid drug dependence (as part of a medical, social, and psychological treatment program).
Pain Management: Management of severe chronic pain that does not respond to non-opioid analgesics.
Dosage & Administration
The Sublingual Mandate (CRITICAL): The tablet must not be swallowed, crushed, or chewed. It must be placed under the tongue until completely dissolved. Swallowing the tablet results in near-zero efficacy.
Induction Phase: Treatment must only start when the patient is in clear signs of moderate withdrawal to avoid “Precipitated Withdrawal.”
Safety Warning: Risk of Precipitated Withdrawal if taken too soon after other opioids. Although it has a “Ceiling Effect,” it should never be combined with Benzodiazepines or Alcohol due to the risk of fatal respiratory failure. Use with caution in patients with severe hepatic impairment.
Global Export & Contract Manufacturing
Healthy Inc is a premier Narcotic Pharmaceutical Exporter in India. As a verified Specialized Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for scheduled CNS drugs. Whether you are an Addiction Recovery Network in Africa or a B2B Pharma Marketplace partner in the CIS, we ensure secure, WHO-GMP and Narcotic-compliant delivery.
Reviews
There are no reviews yet.